Revolution Medicines · 1 day ago
Scientist I, Clinical Biomarker Development (Cancer Genomics)
San Francisco Bay Area
Full-time
Onsite
New Grad, Entry Level
$115K/yr - $144K/yrRevolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies for RAS-addicted cancers. The Cancer Genomics Scientist I will apply advanced analytics and genomics solutions to clinical biomarker data, collaborate with cross-functional teams, and communicate findings to various audiences.
Health CareLife ScienceMedical
Responsibilities
Apply advanced analytics and genomics solutions to clinical biomarker data to inform research & development, including machine learning methods with high throughput NGS genomic data
Integrate multi-omics datasets (e.g. spatial transcriptomics, liquid biopsy, and other NGS approaches) to interrogate disease biology, resistance mechanisms, and predict drug response
Collaborate with cross functional teams, managing interactions with key stakeholders to deliver robust biomarker analyses and recommend follow up actions
Communicate results to expert and non-expert audiences, including internal cross-functional team members and external collaborators, through scientific publications and presentations
Qualification
Required
A Ph.D. in Cancer Genomics, Genetics, Computational Biology, or similar degree in which cancer biology is integrated with genomics data analysis
Proficiency programming in R and/or Python for computational biology analysis
Expert in clearly documenting work with a version control system (git)
Experienced in Linux and the cloud, including HPC clusters and command line interface
Practiced at developing genomics workflows for large scale NGS datasets
Expert in the interrogation of RNAseq data, such as bulk, single-cell, and spatial transcriptomics data, preferably including utilization of single-cell atlas data to inform analysis flow
Experienced working with DNA sequence data (mutation, liquid biopsy, CGP, WES, or similar)
Practiced in commonly used tools and methods (Seurat, Scanpy, GATK, Bioconductor, etc) and in utilizing publicly available datasets (TCGA, cBioPortal) to interrogate cancer genomics data
Strong interpersonal, verbal and written communication skills; proactive, self-motivated, and adaptable in a dynamic environment
Demonstrated ability to translate complex data into clear biological insight, and to influence project direction through data-driven scientific inquiry
Preferred
Experienced with AI/ML approaches to integrate single-cell & spatial transcriptomics data
Deep knowledge of pancreatic cancer, preferably including how progression, response and resistance may be mediated by tumor microenvironment and/or transcriptional programming
Trained in cancer signaling biology with strong understanding of RAS/MAPK signaling pathways
Strong understanding of statistics and the ability to generate robust predictive models for outcomes in multidimensional data
Benefits
Competitive cash compensation
Robust equity awards
Strong benefits
Significant learning and development opportunities
Company
Revolution Medicines
Revolution Medicines is an innovative and dynamic organization of expert biologists, chemists, pharmacologists, clinical scientists.
Founded in 2015
501-1000 employees
H1B Sponsorship
Revolution Medicines has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (13)
2024 (18)
2023 (15)
2022 (8)
2021 (1)
2020 (2)
Funding
Current Stage
Public CompanyTotal Funding
$2.25BKey Investors
Royalty PharmaBoxer CapitalNextech Invest
2025-06-24Post Ipo Debt· $250M
2024-12-02Post Ipo Equity· $750M
2023-03-02Post Ipo Equity· $323.6M
Leadership Team
Luan Wilfong
Chief Human Resources Officer
Steve Kelsey
President
Recent News
2026-01-09
2026-01-09
Company data provided by crunchbase